Table 2.

Baseline and post-treatment (post-tx) performance on tasks of sustained attention, episodic memory, and working memory (0 mg, 3 mg, 6 mg rivastigmine).

Index	Placebo 0 mg (N = 16)		Rivastigmine 3 mg (N = 13)		Rivastigmine 6 mg (N = 12)
	Baseline	Post-tx	Baseline	Post-tx	Baseline	Post-tx
CPT-II^
Hit rate – RT^^	51.01 ± 3.96	46.58 ± 3.63	55.62 ± 4.88	52.46 ± 3.30	45.84 ± 4.10	44.26 ± 3.90
Omissions	79.66 ± 10.93	60.08 ± 4.76	100.46 ± 15.24	61.71 ± 6.95	87.95 ± 24.12	56.82 ± 7.37
Commissions	51.99 ± 2.35	52.46 ± 3.08	56.31 ± 3.04	50.59 ± 2.54	50.35 ± 2.79	48.76 ± 2.29
HVLT—R
Trials 1–3 (scaled)	33.31 ± 2.78	32.13 ± 2.02	34.23 ± 2.54	37.69 ± 2.31	38.75 ± 3.31	42.08 ± 1.87
DR (scaled)	32.38 ± 2.65	31.38 ± 2.71	39.46 ± 2.43	34.92 ± 2.69	37.75 ± 2.72	39.33 ± 3.86
N-back
Aud accuracy	0.50 ± .05	0.52 ± .05	.63 ± .03	.59 ± .03	.62 ± .05	.66 ± .03
Vis accuracy	0.43 ± .05	0.50 ± .05	.51 ± .02	.55 ± .02	.50 ± .06	.55 ± .06
N-value (mean)	1.46 ± .11	1.54 ± .10	1.51 ± .09	1.72 ± .12	1.60 ± .13	1.94 ± .11
N-value (max)	2.06 ± .19	2.06 ± .17	2.31 ± .13	2.54 ± .14	2.42 ± .23	2.67 ± .19

Values represent Mean ± SEM.

^{^}Higher scores are indicative of poorer performance.

^{^^}RT = reaction time.